Ironwood Pharmaceuticals (IRWD) News Today $0.89 +0.01 (+1.12%) Closing price 04:00 PM EasternExtended Trading$0.88 -0.01 (-1.29%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Ironwood Pharmaceuticals (IRWD) Boosts Earnings Outlook for 2025April 25 at 5:43 PM | gurufocus.comIronwood Pharmaceuticals hikes adjusted EBITDA guidance to greater than $105M, shares riseApril 25 at 12:03 PM | msn.comIronwood Pharmaceuticals (IRWD) Boosts FY25 EBITDA Forecast Amid Strong Demand | IRWD Stock NewsApril 25 at 8:12 AM | gurufocus.comIronwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA GuidanceApril 25 at 7:05 AM | businesswire.comIronwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral SupportApril 22 at 4:05 PM | businesswire.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Short Interest Down 30.8% in MarchIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) was the recipient of a significant decrease in short interest in the month of March. As of March 31st, there was short interest totalling 11,250,000 shares, a decrease of 30.8% from the March 15th total of 16,250,000 shares. Based on an average daily volume of 3,230,000 shares, the days-to-cover ratio is currently 3.5 days. Approximately 7.2% of the company's shares are sold short.April 20, 2025 | marketbeat.comIronwood Pharmaceuticals (NASDAQ:IRWD) Stock Rating Lowered by Craig HallumCraig Hallum lowered Ironwood Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Wednesday.April 20, 2025 | marketbeat.comLeerink Partnrs Has Strong Forecast for IRWD Q2 EarningsIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Investment analysts at Leerink Partnrs upped their Q2 2025 earnings estimates for Ironwood Pharmaceuticals in a research report issued on Monday, April 14th. Leerink Partnrs analyst F. Khurshid now expects that the biotechnology companyApril 19, 2025 | marketbeat.comIronwood Pharmaceuticals (NASDAQ:IRWD) Cut to Hold at Craig HallumApril 19, 2025 | americanbankingnews.comLeerink Partnrs Issues Positive Outlook for IRWD EarningsApril 19, 2025 | americanbankingnews.comResearch Analysts Offer Predictions for IRWD Q3 EarningsIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Equities researchers at Leerink Partnrs increased their Q3 2025 earnings estimates for Ironwood Pharmaceuticals in a research report issued to clients and investors on Monday, April 14th. Leerink Partnrs analyst F. Khurshid now forecastApril 18, 2025 | marketbeat.comLeerink Partnrs Issues Optimistic Outlook for IRWD EarningsApril 18, 2025 | americanbankingnews.comIronwood Pharmaceuticals (NASDAQ:IRWD) Downgraded by StockNews.com to "Hold"StockNews.com lowered shares of Ironwood Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Tuesday.April 17, 2025 | marketbeat.comIronwood Pharmaceuticals' (IRWD) "Equal Weight" Rating Reaffirmed at Wells Fargo & CompanyWells Fargo & Company reiterated an "equal weight" rating and issued a $1.00 price objective (down from $7.00) on shares of Ironwood Pharmaceuticals in a research report on Tuesday.April 17, 2025 | marketbeat.comJefferies Financial Group Reaffirms "Hold" Rating for Ironwood Pharmaceuticals (NASDAQ:IRWD)Jefferies Financial Group reissued a "hold" rating and set a $0.70 price objective (down from $8.00) on shares of Ironwood Pharmaceuticals in a report on Tuesday.April 17, 2025 | marketbeat.comIronwood Pharma (IRWD) was downgraded to a Hold Rating at Craig-HallumApril 17, 2025 | markets.businessinsider.comIronwood Pharmaceuticals (NASDAQ:IRWD) Downgraded by StockNews.com to HoldApril 17, 2025 | americanbankingnews.comLeerink Partners Has Lowered Expectations for Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock PriceLeerink Partners lowered their target price on Ironwood Pharmaceuticals from $3.00 to $1.00 and set a "market perform" rating for the company in a research note on Monday.April 16, 2025 | marketbeat.comIronwood Pharmaceuticals (IRWD) Faces Downgrade and Challenges Amid FDA Trial Delay | IRWD ...April 16, 2025 | gurufocus.comIronwood Pharmaceuticals (IRWD) Faces Setback After FDA RequestApril 16, 2025 | gurufocus.comIronwood Pharmaceuticals (NASDAQ:IRWD) Stock Rating Lowered by Citizens JmpCitizens Jmp downgraded Ironwood Pharmaceuticals from an "outperform" rating to a "market perform" rating in a research report on Monday.April 16, 2025 | marketbeat.comIronwood Pharmaceuticals (NASDAQ:IRWD) Rating Lowered to "Market Perform" at Citizens JmpApril 16, 2025 | americanbankingnews.comIronwood Pharma Provides Update On Apraglutide; Plans Strategic AlternativesApril 16, 2025 | nasdaq.comIronwood downgraded to Hold from Buy at JefferiesApril 15, 2025 | markets.businessinsider.comWells Fargo Downgrades Ironwood Pharmaceuticals (IRWD)April 15, 2025 | msn.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares Sold by LSV Asset ManagementLSV Asset Management reduced its stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 19.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,081,501 shares of the biotechnology company's stockApril 15, 2025 | marketbeat.comIronwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal DrugApril 14, 2025 | benzinga.comIronwood Pharmaceuticals Stock Plunges, FDA Wants Another Trial For Gastrointestinal DrugApril 14, 2025 | benzinga.comIronwood Pharmaceuticals stock tumbles after FDA requires additional trialApril 14, 2025 | au.investing.comIronwood looks for strategic options after regulatory hurdle for lead drugApril 14, 2025 | msn.comIronwood Pharmaceuticals (IRWD) Considers Strategic Options After FDA SetbackApril 14, 2025 | gurufocus.comIronwood Pharmaceuticals Provides Clinical and Regulatory Update on ApraglutideApril 14, 2025 | gurufocus.comIronwood Pharmaceuticals Provides Clinical and Regulatory Update on ApraglutideApril 14, 2025 | finance.yahoo.comIronwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide | IRWD Stock NewsApril 14, 2025 | gurufocus.comRenaissance Technologies LLC Acquires 469,043 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)Renaissance Technologies LLC grew its stake in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 5.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 9,066,241 sApril 13, 2025 | marketbeat.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Rating of "Moderate Buy" by BrokeragesIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six ratings firms that are covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and three have assigned a buyApril 13, 2025 | marketbeat.comVanguard Group Inc. Cuts Stock Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)Vanguard Group Inc. lessened its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 11.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,538,555 shares ofApril 12, 2025 | marketbeat.comIronwood Pharmaceuticals: Setting A Strong Foundation For A Return To GrowthApril 10, 2025 | seekingalpha.comSei Investments Co. Cuts Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)Sei Investments Co. cut its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 65.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 141,915 shares of the biotechnology company's stock after selApril 10, 2025 | marketbeat.com10 Stocks Fall Behind Amid Market OptimismApril 10, 2025 | insidermonkey.comIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Short Interest Up 34.9% in MarchIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) was the target of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 16,250,000 shares, an increase of 34.9% from the February 28th total of 12,050,000 shares. Based on an average daily trading volume, of 3,340,000 shares, the days-to-cover ratio is currently 4.9 days. Currently, 10.5% of the company's stock are sold short.April 1, 2025 | marketbeat.comIronwood Pharmaceuticals: Stability and Growth Potential Amid Internal Control ImprovementsMarch 31, 2025 | tipranks.comIronwood Pharmaceuticals (NASDAQ:IRWD) Rating Increased to Buy at StockNews.comStockNews.com upgraded shares of Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday.March 30, 2025 | marketbeat.comZacks Research Analysts Decrease Earnings Estimates for IRWDIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Zacks Research reduced their Q3 2026 earnings per share estimates for Ironwood Pharmaceuticals in a research note issued on Wednesday, March 26th. Zacks Research analyst R. Department now expects that the biotechnology company will postMarch 29, 2025 | marketbeat.comIronwood receives Nasdaq non-compliance notificationMarch 28, 2025 | markets.businessinsider.comIronwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K FilingMarch 27, 2025 | businesswire.comIndustry Veteran Launches Ironwood III With Substantial Equity Commitment From Kayne Anderson Energy Infrastructure FundMarch 25, 2025 | businesswire.comEquities Analysts Offer Predictions for IRWD Q2 EarningsIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Analysts at Zacks Research dropped their Q2 2025 EPS estimates for Ironwood Pharmaceuticals in a report issued on Thursday, March 20th. Zacks Research analyst R. Department now forecasts that the biotechnology company will post earningsMarch 24, 2025 | marketbeat.comIronwood Pharmaceuticals (NASDAQ:IRWD) Rating Lowered to "Hold" at StockNews.comStockNews.com lowered Ironwood Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday.March 21, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Buys 215,166 Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)Connor Clark & Lunn Investment Management Ltd. boosted its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 170.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 341,455 shMarch 20, 2025 | marketbeat.com Get Ironwood Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter. Email Address IRWD Media Mentions By Week IRWD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IRWD News Sentiment▼0.540.74▲Average Medical News Sentiment IRWD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IRWD Articles This Week▼125▲IRWD Articles Average Week Get Ironwood Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Zenas Biopharma News Verastem News Rigel Pharmaceuticals News XOMA News Vanda Pharmaceuticals News Emergent BioSolutions News Codexis News Sangamo Therapeutics News Lexicon Pharmaceuticals News Regulus Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IRWD) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ironwood Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ironwood Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
